This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

About

Efficacy

Safety & Tolerability

Real World Experience

Support & Resources

Information on how to access XELJANZ®▼ (tofacitinib citrate) prescribing information and adverse event reporting can be found at the bottom of the page.

Safety Profile

XELJANZ demonstrates a consistent safety profile in PsA - building on experience in RA1-8

  • XELJANZ has been studied in two large Phase III PsA clinical trials1–4 and one LTE study up to 4 years, and shows a safety profile consistent with that observed in RA5,6
  • A clinical trial programme in RA, including LTE studies up to 9.5 years5
  • Real-world experience: XELJANZ has been prescribed to over 208,000 patients across indications worldwide7 


System organ class

Common (>1/100 to <1/10)

Infections and infestations

Pneumonia, influenza, herpes zoster, urinary tract infection, sinusitis, bronchitis, nasopharyngitis, pharyngitis

Blood and lymphatic system disorders

Anaemia

Nervous system disorders

Headache

Vascular disorders

Hypertension

Respiratory, thoracic and mediastinal disorders

Cough

Gastrointestinal disorders

Abdominal pain, vomiting, diarrhoea, nausea, gastritis, dyspepsia

Skin and subcutaneous tissue disorders​​​​​​​

Rash

Musculoskeletal and connective tissue disorders

Arthralgia

General disorders and administration site conditions

Oedema peripheral, pyrexia, fatigue

Investigations

Blood creatine phosphokinase increased

Explore more

Dosing in PsA

Visit page


LTE=long-term extension; PsA=psoriatic arthritis; RA = rheumatoid arthritis

  1. Mease P et al. N Engl J Med 2017; 377: 1537–1550.
  2. Mease P et al. N Engl J Med 2017; 377: 1537–1550 (supplementary appendix).
  3. Gladman D et al. N Engl J Med 2017; 377: 1525–1536.
  4. Gladman D et al. N Engl J Med 2017; 377: 1525–1536 (supplementary appendix).
  5. Wollenhaupt J et al. Poster presented at: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting; November 3–8, 2017; San Diego, CA, USA.
  6. Nash P et al. Lancet Rehumatol. 2021;3(4):E27-E283.
  7. Cohen SB et al. Lancet Rheumatol. 2019; 1:e23-e34.
  8. XELJANZ (tofacitinib citrate) Summary of Product Characteristics.
PP-XEL-GBR-2320. June 2021

Title

XELJANZ Risk Minimisation Programme (RMP) materials, including a Patient Alert Card, Prescriber Checklists and a Prescriber Brochure are available from
https://www.medicines.org.uk/emc/. Patients treated with XELJANZ should be given the Patient Alert Card.

Clinical Efficacy PsA

View Support & Services

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes

No